Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors who suffered losses are urged to file lead plaintiff motions by October 13, 2026.